MISSISSAUGA, ON, Nov. 24,
2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH)
("Cipher" or "the Company") today announced that it
has changed its auditors from Ernst & Young LLP ("Former
Auditor") to RSM Canada LLP ("Successor Auditor") effective
November 23, 2023. At the request of
the Company, the Former Auditor resigned as the auditor of the
Company effective November 23, 2023
and the board of directors of the Company appointed the Successor
Auditor as the Company's auditor effective November 23, 2023, until the next Annual General
Meeting of the Company.
There were no reservations in the Former Auditor's audit reports
for any financial period during which the Former Auditor was the
Company's auditor. There are no "reportable events" (as the term is
defined in National Instrument 51-102 – Continuous Disclosure
Obligations ("NI 51-102")) between the Company and the Former
Auditor.
In accordance with NI 51-102, the notice of change of auditor,
together with the required letters from the Former Auditor and the
Successor Auditor, have been reviewed by the board of directors of
the Company and filed on SEDAR+ at www.sedarplus.ca.
About Cipher Pharmaceuticals
Inc.
Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical
company with a robust and diversified portfolio of commercial and
early to late-stage products. Cipher acquires products that fulfill
unmet medical needs, manages the required clinical development and
regulatory approval process, and currently markets those products
either directly in Canada or indirectly through partners
in Canada, the U.S. and South America. For more
information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
